Alliance for Regenerative Medicine Annual Report Highlights Record Sector Growth and Resilience in 2020

March 16, 2021

Washington, DC

The regenerative medicine and advanced therapies sector raised a record $19.9B in funding in 2020, fueling the broader biotech sector and driving a rapidly advancing pipeline of potentially transformative therapies, according to the Alliance for Regenerative Medicine’s (ARM) 2020 Annual Report released today.


Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan

February 3, 2021

WASHINGTON, DC and BRUSSELS, BELGIUM

The Alliance for Regenerative Medicine (ARM) – the ‘global voice’ of the regenerative medicine and advanced therapies sector – applauds the EU Beating Cancer Plan’s identification of Advanced Therapy Medicinal Products (ATMPs) as part of a comprehensive cancer solution. ATMPs include cell and gene therapies that have already revolutionized the treatment of some aggressive forms of blood cancers and hold great promise for addressing other types of cancer.


ARM Statement on the Trump Administration's Interim Final MFN Rule

January 26, 2021

Washington, DC


ARM Responds to EU Pharmaceutical Strategy

November 25, 2020

Washington, DC

The EU Pharmaceutical Strategy recognizes cell and gene therapies as ‘major milestones’ of progress in healthcare, which can durably treat or even cure the most challenging diseases. We are reviewing today’s strategy document in detail and believe that innovative regulatory and payment policies are crucial to ensuring patient access to these transformative therapies. We look forward to engaging with the European Commission and other stakeholders to develop a conducive, holistic environment for advanced therapies and the life-changing benefits they bring to patients.